Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirtazapine and low-FODMAP diet in IBS-D
NCT06684470Phase 1Recruiting
- Sponsor
- Mayo Clinic
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mirtazapine in irritable bowel syndrome (IBS), sponsored by Mayo Clinic. Primary endpoint: Resolution of Irritable Bowel Syndrome at 49 days. Started Dec 2024; status: recruiting.
02
Drugs
mirtazapine
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT06684470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06684470.